Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $11.36.
Several brokerages have issued reports on VOR. Robert W. Baird lowered their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a research note on Friday, November 8th. HC Wainwright reiterated a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Wedbush reiterated an "outperform" rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Monday, December 9th. Finally, JMP Securities restated a "market outperform" rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Tuesday, December 10th.
Check Out Our Latest Report on Vor Biopharma
Institutional Investors Weigh In On Vor Biopharma
Several large investors have recently modified their holdings of the company. Two Sigma Investments LP boosted its holdings in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $33,000. Northern Trust Corp lifted its holdings in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares during the period. Virtu Financial LLC acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $60,000. Finally, XTX Topco Ltd acquired a new stake in shares of Vor Biopharma during the fourth quarter worth $80,000. 97.29% of the stock is owned by institutional investors and hedge funds.
Vor Biopharma Trading Up 2.3 %
VOR traded up $0.02 on Friday, hitting $0.90. 421,920 shares of the company's stock were exchanged, compared to its average volume of 612,977. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.43. The firm has a 50-day moving average price of $1.33 and a 200-day moving average price of $1.01. The stock has a market cap of $61.81 million, a price-to-earnings ratio of -0.55 and a beta of -0.45.
About Vor Biopharma
(
Get Free ReportVor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Read More
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
